Sei Shu

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model.

Polatuzumab Vedotin Enhances Intratumoral T-Cell Infiltration and Demonstrates Combinatorial Efficacy With Anti-CD20/CD3 Bispecific Antibody in a Syngeneic B-Cell Malignancy Mouse Model.

Journal: EJHaem
Published: March 30, 2026

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models.

Innate Immune Cell Infiltration Induced by Polatuzumab Vedotin Contributes to the Antitumor Effect in Mouse Models.

Journal: EJHaem
Published: August 01, 2025

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.

Polatuzumab Vedotin Induced CD20 Upregulation Contributes to the Efficacy of Mosunetuzumab in Combination With Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma Preclinical Models.

Journal: EJHaem
Published: May 03, 2025

Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.

Correction to: Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.

Journal: Cancer chemotherapy and pharmacology
Published: December 18, 2020

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.

Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation.

Journal: Cancer chemotherapy and pharmacology
Published: March 16, 2020

Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.

Trastuzumab in combination with paclitaxel enhances antitumor activity by promoting apoptosis in human epidermal growth factor receptor 2-positive trastuzumab-resistant gastric cancer xenograft models.

Journal: Anti-cancer drugs
Published: October 22, 2019

The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells.

The balance of forces generated by kinesins controls spindle polarity and chromosomal heterogeneity in tetraploid cells.

Journal: Journal of cell science
Published: February 28, 2019

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.

Changes in HER2 Expression and Amplification Status Following Preoperative Chemotherapy for Gastric Cancer.

Journal: In vivo (Athens, Greece)
Published: July 24, 2018

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.

Molecular targeting of HER2-overexpressing biliary tract cancer cells with trastuzumab emtansine, an antibody-cytotoxic drug conjugate.

Journal: Cancer chemotherapy and pharmacology
Published: July 24, 2018

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.

Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.

Journal: BMC cancer
Published: May 10, 2018

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model.

Journal: Oncology letters
Published: December 09, 2015

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.

Overexpression and gene amplification of EGFR, HER2, and HER3 in biliary tract carcinomas, and the possibility for therapy with the HER2-targeting antibody pertuzumab.

Journal: Journal of gastroenterology
Published: May 15, 2014
Showing 1-12 of 14

Last Updated: 09/26/2026